Compare TRAK & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRAK | CRBU |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.5M | 203.9M |
| IPO Year | 1998 | 2021 |
| Metric | TRAK | CRBU |
|---|---|---|
| Price | $10.38 | $1.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 81.0K | ★ 1.2M |
| Earning Date | 02-17-2026 | 03-09-2026 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | ★ 19.98 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $23,136,391.00 | $9,295,000.00 |
| Revenue This Year | $8.29 | $0.22 |
| Revenue Next Year | $24.17 | $4.48 |
| P/E Ratio | $28.67 | ★ N/A |
| Revenue Growth | ★ 11.05 | N/A |
| 52 Week Low | $10.03 | $0.66 |
| 52 Week High | $23.72 | $3.54 |
| Indicator | TRAK | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 35.10 | 46.47 |
| Support Level | $10.03 | $1.48 |
| Resistance Level | $10.75 | $1.65 |
| Average True Range (ATR) | 0.44 | 0.11 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 15.86 | 38.89 |
ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.